Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Rinaldi

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Plos One|August 30, 2017
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritisMarco Puthenparampil, Lisa Federle, Davide Poggiali, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|June 12, 2018
Post-transplant liver graft schistosomiasis in a migrant from Sub-Saharan AfricaPaola Carrai, Lorenzo Zammarchi, Luca Emanuele Pollina, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 16, 2010
No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up studyLuciano Rinaldi, Francesca Rinaldi, Paola Perini, et al.
RSC Advances|May 11, 2022
Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity against <i>Mycobacterium tuberculosis</i>Francesca Rinaldi, Sara Tengattini, Luciano Piubelli, et al.
Multiple Sclerosis and Related Disorders|March 31, 2026
EDSS and disease duration associate with progression independent of relapse and MRI activity in natalizumab-treated multiple sclerosis patientsMarco Puthenparampil, Margherita Passamonti, Martina Rozzi, et al.
Frontiers in Immunology|April 1, 2026
The cytokine signature in multiple sclerosis: a study during the SARS-CoV-2 pandemicMarco Puthenparampil, Annachiara Marin, Federica De Napoli, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 14, 2024
High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple SclerosisMarco Puthenparampil, Marta Gaggiola, Marta Ponzano, et al.
Human Brain Mapping|October 13, 2020
Early red nucleus atrophy in relapse-onset multiple sclerosisMonica Margoni, Davide Poggiali, Sofia Zywicki, et al.
Neurological Research and Practice|November 14, 2025
The clinical relevance of hyper-reflective foci in the inner retina at the diagnosis of multiple sclerosisMarco Puthenparampil, Alessandro Miscioscia, Elisa Basili, et al.
Therapeutic Advances in Neurological Disorders|October 9, 2023
Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosisMarco Puthenparampil, Marta Gaggiola, Alessandro Miscioscia, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Plos One|August 30, 2017
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritisMarco Puthenparampil, Lisa Federle, Davide Poggiali, et al.
Transplant Infectious Disease : an Official Journal of the Transplantation Society|June 12, 2018
Post-transplant liver graft schistosomiasis in a migrant from Sub-Saharan AfricaPaola Carrai, Lorenzo Zammarchi, Luca Emanuele Pollina, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 16, 2010
No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up studyLuciano Rinaldi, Francesca Rinaldi, Paola Perini, et al.
RSC Advances|May 11, 2022
Rational design, preparation and characterization of recombinant Ag85B variants and their glycoconjugates with T-cell antigenic activity against <i>Mycobacterium tuberculosis</i>Francesca Rinaldi, Sara Tengattini, Luciano Piubelli, et al.
Multiple Sclerosis and Related Disorders|March 31, 2026
EDSS and disease duration associate with progression independent of relapse and MRI activity in natalizumab-treated multiple sclerosis patientsMarco Puthenparampil, Margherita Passamonti, Martina Rozzi, et al.
Frontiers in Immunology|April 1, 2026
The cytokine signature in multiple sclerosis: a study during the SARS-CoV-2 pandemicMarco Puthenparampil, Annachiara Marin, Federica De Napoli, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 14, 2024
High NEDA and No PIRA in Natalizumab-Treated Patients With Pediatric-Onset Multiple SclerosisMarco Puthenparampil, Marta Gaggiola, Marta Ponzano, et al.
Human Brain Mapping|October 13, 2020
Early red nucleus atrophy in relapse-onset multiple sclerosisMonica Margoni, Davide Poggiali, Sofia Zywicki, et al.
Neurological Research and Practice|November 14, 2025
The clinical relevance of hyper-reflective foci in the inner retina at the diagnosis of multiple sclerosisMarco Puthenparampil, Alessandro Miscioscia, Elisa Basili, et al.
Therapeutic Advances in Neurological Disorders|October 9, 2023
Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosisMarco Puthenparampil, Marta Gaggiola, Alessandro Miscioscia, et al.
Pageof 12